83314-01-6
83314-01-6 結(jié)構(gòu)式
基本信息
化合物 T14831
CS-1164
NSC-339555
BRYOSTATIN
Byrostatin 1
BRYOSTATIN 1
bryostatin1,0
(26R)-Bryostatin 1
Bryostatin 1 - CAS 83314-01-6 - Calbiochem
(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(Acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-Methoxy-2-oxoethylidene)-10,10,26,26-tetraMethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-y
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-105231 | 化合物 T14831 Bryostatin 1 | 83314-01-6 | 10μg | 5200元 |
常見問題列表
PKC
HIV-1
Bryostatin 1 (1 μM; 5 minutes; HT22 cells) treatment successfully recruits Munc13-1 from the cytosol to the plasma membrane. Effects of Bryostatin 1 on the other Munc13 family members, ubMunc13-2 and bMunc13-2, resembled those of Munc13-1 for translocation .
The increased level of expression of Munc13-1 following a 24 h incubation with Bryostatin 1 in both HT22 and primary mouse hippocampal cells is observed.
Bryostatin 1 can also affect the immune system by modulating dendritic cells (DCs) via toll-like receptor 4 (TLR4) through the MyD88-independent pathway, which favors an anti-inflammatory environment by inducing a type 2 phenotype that promotes the differentiation of CD4
+
T-helper (Th) lymphocytes into Th2 versus Th1 effector cells.
Western Blot Analysis
| Cell Line: | HT22 cells |
| Concentration: | 1 μM |
| Incubation Time: | 5 minutes |
| Result: | Caused Munc13-1 to transfer to the membrane fraction. |
Bryostatin 1 (30 μg/kg; intraperitoneal injection; 3 d per week; for 2 weeks; C57BL/6J mice) treatment abolishes the onset of EAE.
| Animal Model: | Female C57BL/6J mice (8-12-week-old) with MOG 35-55 |
| Dosage: | 30 μg/kg |
| Administration: | Intraperitoneal injection; 3 d per week; for 2 weeks |
| Result: | Abolished the onset of experimental autoimmune encephalomyelitis (EAE). |